Literature DB >> 20671020

When budgets are tight, there are better options than colonoscopies for colorectal cancer screening.

Sujha Subramanian1, Georgiy Bobashev, Robert J Morris.   

Abstract

A critical challenge facing cancer screening programs, particularly those aimed at uninsured people with low incomes, is choosing the screening test that makes the most efficient use of limited budgets. For colorectal cancer screening, there is growing momentum to use colonoscopy, which is an expensive test. In this study, we modeled scenarios to assess whether the use of fecal occult blood tests or colonoscopy provides the most benefit under conditions of budget constraints. We found that although colonoscopy is more accurate, under most scenarios, fecal occult blood tests would result in more individuals' getting screened, with more life-years gained.

Entities:  

Mesh:

Year:  2010        PMID: 20671020     DOI: 10.1377/hlthaff.2008.0898

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  18 in total

1.  Screening colonoscopy in the US: attitudes and practices of primary care physicians.

Authors:  Jane Zapka; Carrie N Klabunde; Stephen Taplin; Gigi Yuan; David Ransohoff; Sarah Kobrin
Journal:  J Gen Intern Med       Date:  2012-04-27       Impact factor: 5.128

2.  Costs of colorectal cancer screening provision in CDC's Colorectal Cancer Control Program: Comparisons of colonoscopy and FOBT/FIT based screening.

Authors:  Sujha Subramanian; Florence K L Tangka; Sonja Hoover; Janet Royalty; Amy DeGroff; Djenaba Joseph
Journal:  Eval Program Plann       Date:  2017-02-07

3.  Patients and caregivers costs for colonoscopy-based colorectal cancer screening: Experience of low-income individuals undergoing free colonoscopies.

Authors:  Sonja Hoover; Sujha Subramanian; Florence K L Tangka; Maggie Cole-Beebe; Amy Sun; Cheryl L Kramer; Gina Pacillio
Journal:  Eval Program Plann       Date:  2017-01-07

4.  Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina.

Authors:  Alex van der Steen; Amy B Knudsen; Frank van Hees; Gailya P Walter; Franklin G Berger; Virginie G Daguise; Karen M Kuntz; Ann G Zauber; Marjolein van Ballegooijen; Iris Lansdorp-Vogelaar
Journal:  Health Serv Res       Date:  2014-10-16       Impact factor: 3.402

5.  What Happened to Disparities in CRC Screening Among FFS Medicare Enrollees Following Medicare Modernization?

Authors:  Lee R Mobley; Tzy-Mey Kuo; Mei Zhou; Yamisha Rutherford; Seth Meador; Julia Koschinsky
Journal:  J Racial Ethn Health Disparities       Date:  2018-09-19

6.  Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Authors:  Elisabeth F P Peterse; Reinier G S Meester; Andrea Gini; Chyke A Doubeni; Daniel S Anderson; Franklin G Berger; Ann G Zauber; Iris Lansdorp-Vogelaar
Journal:  Health Aff (Millwood)       Date:  2017-12       Impact factor: 6.301

7.  Costs of promoting cancer screening: Evidence from CDC's Colorectal Cancer Control Program (CRCCP).

Authors:  Florence K L Tangka; Sujha Subramanian; Sonja Hoover; Janet Royalty; Kristy Joseph; Amy DeGroff; Djenaba Joseph; Sajal Chattopadhyay
Journal:  Eval Program Plann       Date:  2016-12-12

Review 8.  Bringing an organizational perspective to the optimal number of colorectal cancer screening options debate.

Authors:  Melissa R Partin; Adam A Powell; Diana J Burgess; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2011-09-14       Impact factor: 5.128

9.  A conceptual framework and metrics for evaluating multicomponent interventions to increase colorectal cancer screening within an organized screening program.

Authors:  Sujha Subramanian; Sonja Hoover; Florence K L Tangka; Amy DeGroff; Cynthia S Soloe; Laura C Arena; Dara F Schlueter; Djenaba A Joseph; Faye L Wong
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

10.  Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention.

Authors:  John Bian; Charles L Bennett; Deborah A Fisher; Maria Ribeiro; Joseph Lipscomb
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.